$3.87 Billion is the total value of RTW INVESTMENTS, LP's 107 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Sell | PTC THERAPEUTICS INC | $202,115,000 | +3.8% | 5,045,307 | -3.4% | 5.22% | +29.5% |
| VCEL | Sell | VERICEL CORP | $88,707,000 | -42.2% | 3,522,904 | -12.3% | 2.29% | -27.9% |
| AXNX | Sell | AXONICS INC | $66,869,000 | -38.7% | 1,179,965 | -32.3% | 1.73% | -23.5% |
| GMED | Sell | GLOBUS MED INCcl a | $62,963,000 | -49.3% | 1,121,527 | -33.3% | 1.63% | -36.7% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $54,610,000 | -53.3% | 922,630 | -8.2% | 1.41% | -41.7% |
| CCCC | Sell | C4 THERAPEUTICS INC | $23,335,000 | -78.8% | 3,094,825 | -31.7% | 0.60% | -73.5% |
| JNCE | Sell | JOUNCE THERAPEUTICS INC | $13,206,000 | -58.4% | 4,358,433 | -6.9% | 0.34% | -48.2% |
| LUNG | Sell | PULMONX CORP | $10,175,000 | -48.6% | 691,255 | -13.4% | 0.26% | -35.9% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $5,215,000 | -66.2% | 2,849,707 | -50.7% | 0.14% | -57.7% |
| AGEN | Sell | AGENUS INC | $3,073,000 | -65.1% | 1,583,822 | -55.8% | 0.08% | -56.6% |
| Sell | PYXIS ONCOLOGY INC | $1,624,000 | -81.0% | 682,220 | -67.8% | 0.04% | -76.3% | |
| DNAY | Sell | CODEX DNA INC | $180,000 | -83.2% | 100,000 | -50.0% | 0.01% | -77.3% |
| ZY | Exit | ZYMERGEN INC | $0 | – | -70,000 | -100.0% | -0.00% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -223,725 | -100.0% | -0.01% | – |
| CNTB | Exit | CONNECT BIOPHARMA HLDGS LTDads | $0 | – | -446,564 | -100.0% | -0.03% | – |
| Exit | SOPHIA GENETICS SAordinary shares | $0 | – | -226,589 | -100.0% | -0.04% | – | |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -51,194 | -100.0% | -0.05% | – |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -7,019,610 | -100.0% | -0.13% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -404,029 | -100.0% | -0.29% | – |
| ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -489,014 | -100.0% | -0.33% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -1,906,557 | -100.0% | -0.53% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.